PAR-19-268: Conference for Early Stage HIV/AIDS Researchers Using Nonhuman Primate Models (R13 Clinical Trial Not Allowed)
Internal Deadline: Contact the Office of Research if interested.
External Deadline: AIDS Application Due Date(s) September 10, 2019, by 5:00 PM local time of applicant organization
Award Information: Type: Grant
Estimated Number of Awards: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. ORIP anticipates providing one award.
Anticipated Amount: Application budgets must be less than $75,000 total costs per meeting per year.
Submission Process: PIs must submit their application as a Limited Submission through the Office of Research Application Portal: https://app.wizehive.com/webform/USCgrants
Materials to submit:
- Single Page Proposal Summary (0.5” margins; single-spaced; font type: Arial, Helvetica, or Georgia typeface; font size: 11 pt). Page limit includes references and illustrations. Pages that exceed the 1-page limit will be excluded from review.
- CV – (5 pages maximum)
Link to Award: https://grants.nih.gov/grants/guide/pa-files/PAR-19-268.html
Who May Serve as PI: The PD(s)/PI(s) for the R13 application should be experts in the translation of preclinical NHP models of HIV/AIDS research to human clinical trials. The PD(s)/PI(s) should be associated with a HIV/AIDS clinical trial network and research consortium. Previous experience in organizing similar workshops/conferences is highly desirable.
This Funding Opportunity Announcement (FOA) encourages Research Conference Grant (R13) applications to conduct an intensive workshop/conference/meeting that addresses the needs of early stage HIV/AIDS researchers as they translate their preclinical research from nonhuman primates (NHPs) to human clinical trials. The objectives of the annual meeting(s) supported by this FOA are to provide these early stage HIV/AIDS researchers with guidance on conducting preclinical research to inform HIV/AIDS prevention and treatment strategies for clinical trials; and developing skills related to networking, grantsmanship, career tracking, goal/milestone-oriented project(s); and promoting strategies to enhance reproducibility in biomedical research through rigor and transparency. Applicants for this FOA should be experts in the translation of work on NHPs to human clinical trials and should be associated with a HIV/AIDS clinical trial network and research consortium. Previous experience in organizing similar workshops/conferences is highly desirable.
The funds provided under the R13 grant are envisioned to organize a conference with topics that may include, but are not limited to:
- Infection prevention studies across the lifespan using NHP models;
- Next-generation therapies, including approaches to coinfection/comorbidities and potential cure strategies;
- Critical aspects of human vaccine development, including statistical considerations, host genetics and other factors;
- Methods to translate the results of NHP studies including challenge, treatment, and prevention research to clinical trials in humans;
- Strategies to develop novel HIV/AIDS NHP research programs based on clinical findings in human HIV/AIDS patients;
- Methods to develop milestone-driven projects in HIV/AIDS research;
- Strategies to enhance reproducibility in biomedical research through rigor and transparency;
- Key aspects of career development, including starting a laboratory, securing funding, goal-oriented career tracking, and other related issues;
- Networking early stage HIV/AIDS scholars with their peers and senior/established investigators.
The R13 conference will be open to all interested early-stage investigators working to translate HIV/AIDS research from NHP models to human clinical trials and to senior investigators who will provide information on career development as well as state-of-the-art of HIV/AIDS research.
Visit our Institutionally Limited Submission webpage for updates and other announcements.